Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26998941 | 0.85 | RAB9A (0.48) | ALDH1A1RAB9ACYP17A1KDM4ECYP19A1 | |
| SCHEMBL9102803 | 0.85 | ATM (0.52) | ALDH1A1KDM4EHTT | |
| Hydrochloric Acid SCHEMBL1677705 | 0.83 | CYP17A1 (0.41) | ALDH1A1RAB9ACYP17A1KDM4ECYP3A4 | |
| SCHEMBL12156570 | 0.82 | PPIB (0.45) | HTR2A | |
| SCHEMBL5188876 | 0.82 | HDAC3 (0.50) | RAB9AKDM4E | |
| SCHEMBL557679 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4E | |
| SCHEMBL5479565 | 0.81 | CYP17A1 (0.50) | ALDH1A1RAB9ACYP17A1NAMPTCYP3A4 | |
| SCHEMBL23792274 | 0.81 | ALDH1A1 (0.52) | ALDH1A1KDM4EGLANAMPT | |
| SCHEMBL4967086 | 0.80 | CYP17A1 (0.47) | RAB9ACYP17A1CYP19A1NAMPT | |
| SCHEMBL4948369 | 0.79 | ELANE (0.40) | ALDH1A1RAB9AKDM4EGLAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314217-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7871997-B2 | Cephalosporin compounds | THERAVANCE, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1633759-B1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE INC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080103299-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2008-05-01 | — | — | US | disclosed |
| US-7332471-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7067481-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060128612-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-06-15 | — | — | US | disclosed |
| EP-1633759-A1 | CROSS-LINKED GLYCOPEPTIDE - CEPHALOSPORIN ANTIBIOTICS | Theravance, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-12-30 | — | — | US | disclosed |
| WO-2004113350-A1 | CROSS-LINKED GLYCOPEPTIDE - CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | GYPA, CSGALNACT1, ST3GAL3 | ALDH1A1 3521/4885RAB9A 3567/4885CYP17A1 1682/4885 |
| US-20060128612-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | ALDH1A1 3028/4885RAB9A 3015/4885CYP17A1 1939/4885 |
| US-20080103299-A1 | Cross-linked glycopeptide - cephalosporin antibiotics | CSGALNACT1, GYPA, ST3GAL3 | ALDH1A1 3044/4885RAB9A 2924/4885CYP17A1 1957/4885 |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | ALDH1A1 3044/4885RAB9A 2924/4885CYP17A1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.